BR9914393B1 - método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante - Google Patents

método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante

Info

Publication number
BR9914393B1
BR9914393B1 BRPI9914393A BR9914393A BR9914393B1 BR 9914393 B1 BR9914393 B1 BR 9914393B1 BR PI9914393 A BRPI9914393 A BR PI9914393A BR 9914393 A BR9914393 A BR 9914393A BR 9914393 B1 BR9914393 B1 BR 9914393B1
Authority
BR
Brazil
Prior art keywords
ngf
biologically active
beta
pro
preparation
Prior art date
Application number
BRPI9914393A
Other languages
English (en)
Other versions
BRPI9914393B1 (pt
BR9914393A (pt
Inventor
Grossmann Adelbert
Rattenholl Anke
Schwarz Elisabeth
Rudolph Rainer
Original Assignee
Scil Proteins Gmbh
Wacker Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scil Proteins Gmbh, Wacker Chemie Ag filed Critical Scil Proteins Gmbh
Publication of BR9914393A publication Critical patent/BR9914393A/pt
Publication of BRPI9914393B1 publication Critical patent/BRPI9914393B1/pt
Publication of BR9914393B1 publication Critical patent/BR9914393B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

método para a obtenção de beta-ngf ativo. a invenção refere-se a um método para a produção de beta-ngf biologicamente ativo oriundo da pró-forma prongf. depois da expressão da pró-forma do beta-ngf em uma célula de hospedeiro procariótica, a proteína recombinante é isolada na forma de agregados insolúveis (corpos de inclusão). depois da sua solubilização em um agente de desnaturação forte e a sua conversão subseqüente na conformação natural, que é determinada pelas pontes de dissulfeto presentes no beta-ngf natural, beta-ngf biologicamente ativo é obtido por liberação por ruptura subseqüente da pró-seqüência.
BRPI9914393A 1998-10-09 1999-10-11 método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante BR9914393B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98119077A EP0994188B1 (de) 1998-10-09 1998-10-09 Verfahren zur Gewinnung von aktivem Beta-NGF
EP98119077.0 1998-10-09
PCT/EP1999/007613 WO2000022119A1 (de) 1998-10-09 1999-10-11 VERFAHREN ZUR GEWINNUNG VON AKTIVEM β-NGF

Publications (3)

Publication Number Publication Date
BR9914393A BR9914393A (pt) 2001-06-26
BRPI9914393B1 BRPI9914393B1 (pt) 2021-06-22
BR9914393B1 true BR9914393B1 (pt) 2021-06-22

Family

ID=8232766

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9914393A BR9914393B1 (pt) 1998-10-09 1999-10-11 método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante

Country Status (14)

Country Link
US (2) US8318671B1 (pt)
EP (1) EP0994188B1 (pt)
JP (2) JP4634611B2 (pt)
KR (1) KR100593831B1 (pt)
AT (1) ATE257514T1 (pt)
AU (1) AU765810B2 (pt)
BR (1) BR9914393B1 (pt)
CA (1) CA2346257C (pt)
DE (1) DE59810555D1 (pt)
ES (1) ES2213861T3 (pt)
FR (1) FR17C0007I2 (pt)
NL (1) NL300894I2 (pt)
WO (1) WO2000022119A1 (pt)
ZA (1) ZA200102780B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF
US8066997B2 (en) 2002-12-20 2011-11-29 Anders Nykjaer Modulation of activity of neurotrophins
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
US9617322B2 (en) * 2011-12-19 2017-04-11 Wacker Chemie Ag ProNGF mutants and uses thereof in the production of beta-NGF
CN103880943A (zh) * 2014-01-20 2014-06-25 厦门北大之路生物工程有限公司 一种rhNGF成熟肽的制备方法
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业（上海）股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
EP3406259A1 (en) 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
CN108467428A (zh) * 2018-03-26 2018-08-31 江苏中新医药有限公司 一种清除rhNGF中N端截短及异常变异体的方法
US20210079053A1 (en) 2018-04-27 2021-03-18 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
AU2019343514A1 (en) 2018-09-17 2021-04-15 Chiesi Farmaceutici S.P.A. Agent for treatment of dermatological disorders
CN110093394B (zh) * 2019-05-10 2023-10-03 重庆科润生物医药研发有限公司 一种蛋白包涵体及重组人β-神经生长因子的制备方法
MX2022002833A (es) 2019-09-17 2022-04-06 Chiesi Farm Spa Agente para usarse en el tratamiento o prevencion de trastornos oftalmicos.
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en) 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf isoform for use in the treatment of ocular pathologies
AU2022258342A1 (en) 2021-04-13 2023-11-02 Dompé Farmaceutici S.P.A. Treatment of neuropathic corneal pain with ngf
EP4311554A1 (en) 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology
EP4316505A1 (en) 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en) 2022-09-23 2024-03-27 Dompe' Farmaceutici S.P.A. Ngf for the treatment of spasticity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169762A (en) * 1983-03-03 1992-12-08 Genentech, Inc. Human nerve growth factor by recombinant technology
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5683894A (en) 1988-04-29 1997-11-04 University Of California Recombinant nerve growth factor
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
US5606031A (en) * 1990-04-06 1997-02-25 Lile; Jack Production and purification of biologically active recombinant neurotrophic protein in bacteria
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
AU3564595A (en) * 1994-09-12 1996-03-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Biologically active molecules derived from neurotrophins
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
CA2257122C (en) 1996-06-11 2004-04-06 Boehringer Mannheim Gmbh Method of activating denatured protein
EP0994188B1 (de) 1998-10-09 2004-01-07 Scil proteins GmbH Verfahren zur Gewinnung von aktivem Beta-NGF

Also Published As

Publication number Publication date
DE59810555D1 (de) 2004-02-12
US20100203589A1 (en) 2010-08-12
FR17C0007I1 (fr) 2017-11-17
JP4634611B2 (ja) 2011-02-16
ES2213861T3 (es) 2004-09-01
KR20010083900A (ko) 2001-09-03
AU1034800A (en) 2000-05-01
FR17C0007I2 (fr) 2018-11-09
KR100593831B1 (ko) 2006-06-28
EP0994188B1 (de) 2004-01-07
BR9914393A (pt) 2001-06-26
JP5275306B2 (ja) 2013-08-28
CA2346257A1 (en) 2000-04-20
JP2010280717A (ja) 2010-12-16
US8501439B2 (en) 2013-08-06
AU765810B2 (en) 2003-10-02
ATE257514T1 (de) 2004-01-15
WO2000022119A1 (de) 2000-04-20
ZA200102780B (en) 2002-07-04
CA2346257C (en) 2005-03-01
NL300894I2 (nl) 2018-02-01
JP2002527062A (ja) 2002-08-27
EP0994188A1 (de) 2000-04-19
US8318671B1 (en) 2012-11-27

Similar Documents

Publication Publication Date Title
BR9914393B1 (pt) método para a preparação de pro-ngf biologicamente ativo, bem como uso de pro-ngf recombinante
Poole et al. Analysis of the morphology and function of primary cilia in connective tissues: a cellular cybernetic probe?
BR0211194A (pt) Produção de derivados de queratina solúveis
BRPI0410884A (pt) composição de ração para uso em um animal de estimação, e, método para o controle de peso em um animal de estimação
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
CL2009000648A1 (es) Propeptido bmp-11 modificado en el residuo 98 de una secuencia bmp-11 humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; metodo para preparar el propeptido, celula recombinante; uso del propeptido para tratar desordenes musculares, neuromusculares, metabolicos, y degenerativos de los huesos (divisional sol.224-02).
BRPI0411552A (pt) anticorpos especìficos a esclerostina e métodos para aumentar a mineralização óssea
Lei et al. A new method for xenogeneic bone graft deproteinization: comparative study of radius defects in a rabbit model
WO1996017924A3 (en) Novel hedgehog-derived polypeptides
BR9913763A (pt) Partìculas de polivinilareno, processo para a preparação de partìculas de polivinilareno porosas, e, uso das partìculas
BRPI0514074A (pt) aperfeiçoamentos em composições em bloco para lavatório
NO20050247L (no) Lavmolekylaert oversulfatert polysakkarid
AR069892A1 (es) Furina recombinante libre de proteinas sustancialmente animal y metodos para producirla. composicion.
WO2003046161A3 (de) Verfahren zur ex vivo-expansion und -differenzierung von multipotenten stammzellen
Anyonge et al. New body mass estimates for Canis dirus, the extinct Pleistocene dire wolf
ES2175246T3 (es) Reticulante pobre en reversion.
ES2119779T3 (es) Solubilizacion de proteinas en formas activas.
AR045671A1 (es) Moleculas de union de nogo a y su uso farmaceutico
Zuev et al. The comparative characteristics of stimulators of reparative osteogenesis in the treatment of periodontal diseases
BR0213756A (pt) Sistema e método para configurar remotamente um rádio, e, estrutura de dados em um perfil de usuário localizado em um banco de dados
BR0014634A (pt) Proteìnas dp de trigo e uso das mesmas
JP2005526015A5 (pt)
LI et al. Advances in study of the characteristics of tendon-derived stem cells
WO2004017972A8 (en) Biologic skin repair and enhancement
BR9811531A (pt) Preparação de proteìnas mutadas humanas em células humanas por meio de recombinação homóloga

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: WACKER CHEMIE AG (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/10/1999, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, , QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 23A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2691 DE 02-08-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.